Description

STAMLO 2.5 MG

Indications

STAMLO 2.5 MG, which contains the active ingredient Amlodipine, is primarily indicated for the treatment of hypertension (high blood pressure) and angina pectoris (chest pain). It is often prescribed as part of a comprehensive treatment plan to reduce cardiovascular risk and improve quality of life in patients with these conditions. STAMLO is suitable for use in adults and can be utilized alone or in combination with other antihypertensive agents.

Mechanism of Action

Amlodipine, the active component of STAMLO, is a long-acting dihydropyridine calcium channel blocker. It works by inhibiting the influx of calcium ions into vascular smooth muscle and cardiac muscle. This inhibition leads to relaxation of vascular smooth muscle, resulting in vasodilation, which decreases peripheral vascular resistance and lowers blood pressure. Additionally, Amlodipine reduces the workload on the heart by decreasing myocardial oxygen demand, making it effective in managing angina symptoms.

Pharmacological Properties

STAMLO has a pharmacokinetic profile characterized by a slow onset of action and a long duration of effect. After oral administration, Amlodipine is well absorbed, with peak plasma concentrations occurring approximately 6 to 12 hours post-dose. The bioavailability of Amlodipine is approximately 64-90%. It is extensively metabolized in the liver, primarily by CYP3A4, and has a half-life of approximately 30 to 50 hours, allowing for once-daily dosing. The drug is excreted mainly in urine as metabolites, with less than 10% being excreted unchanged.

Contraindications

STAMLO 2.5 MG is contraindicated in patients with known hypersensitivity to Amlodipine or any of the excipients in the formulation. It should not be used in patients with severe hypotension, shock (including cardiogenic shock), or obstructive coronary artery disease. Additionally, caution is advised in patients with severe hepatic impairment, as this may affect the metabolism and clearance of the drug.

Side Effects

Common side effects associated with STAMLO 2.5 MG include peripheral edema, dizziness, flushing, palpitations, and fatigue. Less frequently, patients may experience abdominal pain, nausea, or headache. Serious side effects, though rare, can include hypotension, bradycardia, and allergic reactions such as rash or angioedema. Patients should be advised to report any unusual or severe symptoms to their healthcare provider promptly.

Dosage and Administration

The recommended starting dose of STAMLO 2.5 MG for adults is one tablet taken orally once daily. Depending on the clinical response, the dose may be increased to a maximum of 10 MG once daily. It is important for patients to take the medication at the same time each day to maintain consistent blood levels. STAMLO can be taken with or without food. Special populations, such as the elderly or those with hepatic impairment, may require dose adjustment based on individual tolerance and response.

Interactions

STAMLO 2.5 MG may interact with various medications, which can alter its efficacy or increase the risk of side effects. Notable interactions include those with other antihypertensive agents, leading to additive hypotensive effects. Concurrent use with CYP3A4 inhibitors, such as certain antifungals (e.g., ketoconazole) and antibiotics (e.g., erythromycin), may increase Amlodipine plasma concentrations. Conversely, CYP3A4 inducers, such as rifampicin, may decrease its effectiveness. Patients should inform their healthcare provider of all medications, including over-the-counter drugs and supplements, to avoid potential interactions.

Precautions

Before initiating treatment with STAMLO 2.5 MG, it is essential to assess the patient’s medical history, particularly for conditions such as heart failure, hepatic impairment, or a history of angina. Patients with aortic stenosis should be monitored closely as Amlodipine may exacerbate the condition. Caution is also warranted in patients with renal impairment, as the drug is primarily excreted through the kidneys. Regular monitoring of blood pressure and heart rate is recommended to ensure therapeutic effectiveness and safety.

Clinical Studies

Numerous clinical studies have evaluated the efficacy and safety of Amlodipine in various populations. In a randomized controlled trial, Amlodipine was shown to significantly reduce systolic and diastolic blood pressure compared to placebo, with a favorable tolerability profile. Another study demonstrated that Amlodipine effectively alleviated angina symptoms and improved exercise tolerance in patients with stable angina. These studies support the use of STAMLO 2.5 MG as a reliable option for managing hypertension and angina in diverse patient populations.

Conclusion

STAMLO 2.5 MG is an effective antihypertensive and antianginal medication that provides significant benefits for patients with high blood pressure and angina. Its mechanism of action as a calcium channel blocker allows for improved vascular relaxation and reduced cardiac workload. While generally well-tolerated, healthcare providers should remain vigilant regarding potential side effects and drug interactions. Informed patient management, including regular monitoring and education on medication adherence, is crucial for optimizing therapeutic outcomes.